The Liver Cirrhosis Therapeutics Market is segmented by Type (Oral and Injection), End-user (Hospitals, Clinics, and Research and academic institutes), and Geography (North America, Europe, Asia, and Rest of World (ROW)). As per the Global Forecast research report 2024-2028 published by Technavio, the market size is estimated to grow by USD 1.94 billion, at a CAGR of 5.58% during the forecast period. There are several companies that are contributing to the market as per this report. Trend towards personalized medicine .
In the evolving global liver cirrhosis therapeutics market, oral medications have emerged as the preferred choice, accounting for a significant market share. This shift towards oral therapies can be attributed to their patient-friendly attributes, including ease of administration and convenience. Notable oral treatments include Obeticholic acid for the management of non-alcoholic steatohepatitis (NASH) and antifibrotic medications for the treatment of liver fibrosis. The pharmaceutical industry's focus on improving patient adherence, coupled with the growing demand for user-friendly treatments, fuels the popularity of oral therapies. Innovative oral formulations targeting specific pathways in liver cirrhosis development underscore the potential and effectiveness of this therapeutic approach.
For insights on company offerings- Request a sample report!
The liver cirrhosis therapeutics market in the region is experiencing significant growth, driven by the escalating prevalence of liver disorders, heightened public awareness, and advanced healthcare infrastructure. In 2020, over 630,000 individuals were diagnosed with liver cirrhosis in the US, reflecting a gradual increase in incidence. This burgeoning patient population has incentivized pharmaceutical companies to invest heavily in research and development, leading to the introduction of innovative treatments. Notably, drugs like Obeticholic acid, which have gained FDA approval for the treatment of liver fibrosis resulting from non-alcoholic steatohepatitis (NASH), have witnessed a marked uptick in utilization within the regional liver cirrhosis therapeutics market.
To access the valuable insights - Download the Free Sample Report
Liver cirrhosis is a severe and often irreversible liver condition characterized by the replacement of normal liver tissue with scar tissue. It is a major global health issue, with key causes including chronic hepatitis B (HBV) and C (HCV) infections, alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). According to a study published in BMC Infectious Diseases, research activities in liver cirrhosis therapeutics are ongoing, with a focus on novel drugs such as Vosevi, Zepatier, and Mavyret for HCV treatment. For HBV, anti-viral drugs are the mainstay of therapy. Lifestyle modifications, including avoiding alcohol consumption and maintaining a healthy diet, are crucial in managing liver cirrhosis. Chronic hepatitis, alcoholic liver disease, and systemic inflammation are significant contributors to liver cirrhosis, as reported in various hepatology journals, including Molecular Hepatology and Frontiers in Medicine. The Liver Transplant Study Investigators (LTSI), International Liver Transplant Society (ILTS), and American Association for the Study of Liver Diseases (AASLD) are some organizations dedicated to advancing liver cirrhosis research and treatment. In addition to liver failure and hepatocellular carcinoma, cirrhosis can lead to numerous complications, emphasizing the need for effective therapeutics.
According to Technavio, the global liver cirrhosis therapeutics market is a segment of the expansive global pharmaceuticals industry, which encompasses entities involved in the research and development (R&D) or manufacturing of various pharmaceutical offerings, including generic and non-generic drugs, veterinary medicines, and biotechnology products. The size of the global healthcare industry, which includes the revenues generated by providers of pharmaceuticals, medical equipment, and life sciences tools and services, is projected to grow significantly due to factors such as the increasing geriatric population and the subsequent rise in the prevalence of liver cirrhosis. The global pharmaceuticals market expansion is anticipated to be driven by this demographic trend, as well as advancements in R&D leading to the introduction of innovative therapeutic solutions for liver cirrhosis. - The Liver Cirrhosis Therapeutics Market is experiencing significant growth, fueled by the . Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
